OPKO Health: New Material Agreement, Termination, & Financial Obligation

TL;DR

**OPKO Health just shook up its financial agreements and took on new debt; watch for impact on future earnings.**

AI Summary

OPKO Health, Inc. filed an 8-K on January 9, 2024, reporting events from January 4, 2024, including the entry into and termination of a material definitive agreement, and the creation of a direct financial obligation. This matters to investors because significant changes to material agreements and new financial obligations can impact the company's future revenue, expenses, and overall financial health, potentially affecting stock valuation.

Why It Matters

Changes to material agreements and new financial obligations can significantly alter OPKO Health's operational landscape and financial commitments, directly influencing its profitability and risk profile.

Risk Assessment

Risk Level: medium — The filing indicates both entry into and termination of material agreements, alongside new financial obligations, which introduces uncertainty regarding the net impact on the company's financial position.

Analyst Insight

Investors should closely monitor OPKO Health's subsequent filings for details on the specific nature and financial implications of the new and terminated agreements, as well as the direct financial obligation, to assess their impact on future earnings and balance sheet.

Key Players & Entities

• OPKO Health, Inc. (company) — the registrant filing the 8-K
• January 4, 2024 (date) — date of the earliest event reported
• January 9, 2024 (date) — date the 8-K was filed

FAQ

Key Financial Figures

• $0.01 — ch registered Common Stock , par value $0.01 per share OPK NASDAQ Global Select M
• $230.0 million — reviously announced private offering of $230.0 million aggregate principal amount of its 3.75%
• $30.0 million — principal amount of 144A Notes includes $30.0 million aggregate principal amount of 144A Note
• $71.1 million — e Company issued and sold approximately $71.1 million aggregate principal amount of its 3.75%
• $55.0 million — he Affiliate Purchasers in exchange for $55.0 million aggregate principal amount of the Compa
• $16.1 million — % Notes "), together with approximately $16.1 million of accrued but unpaid interest thereon,
• $221.4 m — ance of the 144A Notes of approximately $221.4 million, after deducting fees and estimat
• $50.0 million — Company. The Company used approximately $50.0 million of the net proceeds from the offering o
• $0.9067 — mon Stock on January 4, 2024, which was $0.9067 per share. Also, contemporaneously with
• $144.4 million — ase, on the Closing Date, approximately $144.4 million aggregate principal amount of such note
• $146.3 million — fected such repurchases for cash, using $146.3 million of the net proceeds from the offering o
• $1,000 — y period in which the trading price per $1,000 principal amount of Notes for each trad
• $1.15 — itial conversion price of approximately $1.15 per share of Common Stock), subject to

Filing Documents

• opk20240108_8k.htm (8-K) — 50KB
• ex_613098.htm (EX-4.1) — 601KB
• ex_613097.htm (EX-10.1) — 166KB
• ex_613355.htm (EX-10.2) — 66KB
• 0001437749-24-001007.txt ( ) — 1195KB
• opk-20240104.xsd (EX-101.SCH) — 3KB
• opk-20240104_def.xml (EX-101.DEF) — 11KB
• opk-20240104_lab.xml (EX-101.LAB) — 15KB
• opk-20240104_pre.xml (EX-101.PRE) — 11KB
• opk20240108_8k_htm.xml (XML) — 2KB

01

ITEM 1.01. Entry into a Material Definitive Agreement.   On January 9, 2024 (the " Closing Date "), OPKO Health, Inc., a Delaware corporation (the " Company "), completed its previously announced private offering of $230.0 million aggregate principal amount of its 3.75% Convertible Senior Notes due 2029 (the " 144A Notes ") in accordance with the terms of a note purchase agreement (the " 144A Note Purchase Agreement ") entered into on January 4, 2024 by and between by the Company and J.P. Morgan Securities LLC (the " Initial Purchaser ").  The $230.0 million aggregate principal amount of 144A Notes includes $30.0 million aggregate principal amount of 144A Notes purchased on the Closing Date by the Initial Purchaser in accordance with its exercise in full of its option to purchase additional 144A Notes under the 144A Note Purchase Agreement.    Additionally, on the Closing Date, the Company issued and sold approximately $71.1 million aggregate principal amount of its 3.75% Convertible Senior Notes due 2029 (the " Affiliate Notes " and, together with the 144A Notes, the " Notes ") pursuant to the terms of a note purchase agreement entered into on January 4, 2024 (the " Affiliate Note Purchase Agreement ") by and among the Company and certain investors including, Frost Gamma Investments Trust, a trust controlled by Phillip Frost, M.D., the Company's Chairman and Chief Executive Officer, and Jane H. Hsiao, Ph.D., MBA, the Company's Vice-Chairman and Chief Technical Officer (collectively, the " Affiliate Purchasers ").  Pursuant to the Affiliate Note Purchase Agreement, the Company issued and sold the Affiliate Notes to the Affiliate Purchasers in exchange for $55.0 million aggregate principal amount of the Company's existing 5% convertible promissory notes (the " Existing 5% Notes "), together with approximately $16.1 million of accrued but unpaid interest thereon, held by the Affiliate Purchasers.   The Company received net procee

02

ITEM 1.02. Termination of a Material Definitive Agreement.   The information contained in Item 1.01 of this Current Report on Form 8-K with respect to the Company's acquisition of the Existing 5% Notes from the Affiliate Purchasers is incorporated by reference in this Item 1.02.  The Existing 5% Notes, as amended, were to mature in 2025, and the Company retired all Existing 5% Notes upon its acquisition thereof from the Affiliate Purchasers, following which no such notes remain issued or outstanding.  A description of the material terms of the Existing 5% Notes is contained in Note 7 to the Company's unaudited consolidated financial statements contained in the Company's Quarterly Report on Form 10-Q for the quarter ended March 31, 2023, and such description is incorporated by reference in this Item 1.02.  

03

ITEM 2.03. Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant.   The information contained in Item 1.01 of this Current Report on Form 8-K is incorporated by reference in this Item 2.03.  

02

ITEM 3.02. Unregistered Sales of Equity Securities.   The information contained in Item 1.01 of this Current Report on Form 8-K, is incorporated by reference in this Item 3.02.  

Financial Statements and Exhibits

Financial Statements and Exhibits.     (d) Exhibits   Exhibit  No.   Description     4.1   Indenture, dated January 9, 2024, by and between OPKO Health, Inc. and U.S. Bank Trust Company, National Association, as Trustee. 4.2   Form of 3.75% Convertible Senior Note due 2029 (incorporated by reference to Exhibit A of the Indenture filed as Exhibit 4.1 to this Current Report on Form 8-K). 10.1 *   Purchase Agreement, dated January 4, 2024, by and between the Company and J.P. Morgan Securities LLC, as representative of the Initial Purchasers named therein. 10.2 *   Convertible Note Purchase Agreement, dated as of January 4, 2024, by and among the Company and certain investors, including Frost Gamma Investments Trust and Jane H. Hsiao, Ph.D., MBA. 104   Cover Page Interactive Data File (embedded within the Inline XBRL document)   *   Pursuant to Item 601(a)(5) of Regulation S-K, schedules and similar attachments to this exhibit have been omitted because they do not contain information material to an investment or voting decision and such information is not otherwise disclosed in such exhibit. The Company will supplementally provide a copy of any omitted schedule or similar attachment to the U.S. Securities and Exchange Commission or its staff upon request.        

SIGNATURES

SIGNATURES   Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.       OPKO Health, Inc.             By: /s/ Steven D. Rubin Date: January 9, 2024   Name: Steven D. Rubin     Title: Executive Vice President-Administration            

View Full Filing

View this 8-K filing on SEC EDGAR